[go: up one dir, main page]

NO992008L - New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes - Google Patents

New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes

Info

Publication number
NO992008L
NO992008L NO992008A NO992008A NO992008L NO 992008 L NO992008 L NO 992008L NO 992008 A NO992008 A NO 992008A NO 992008 A NO992008 A NO 992008A NO 992008 L NO992008 L NO 992008L
Authority
NO
Norway
Prior art keywords
syndromes
estrogen
enantiomers
cis
prevention
Prior art date
Application number
NO992008A
Other languages
Norwegian (no)
Other versions
NO992008D0 (en
Inventor
Poul Jacobsen
Svend Treppendahl
Paul Stanley Bury
Anders Kanstrup
Lise Brown Christiansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO992008D0 publication Critical patent/NO992008D0/en
Publication of NO992008L publication Critical patent/NO992008L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse ved- rører terapeutisk aktive forbindelser med formel (I) (D en fremgangsmåte for fremstilling av de samme forbindelsene, og farmasøytiske preparater som omfatter forbindelsene. De nye forbindelsene kan anvendes ved forhindring eller behandling av østro- genrelaterte sykdommer eller syndromer.BACKGROUND OF THE INVENTION The present invention relates to therapeutically active compounds of formula (I) (D) a process for the preparation of the same compounds and to pharmaceutical compositions comprising the compounds.

NO992008A 1996-10-28 1999-04-27 New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes NO992008L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK120296 1996-10-28
PCT/DK1997/000482 WO1998018775A1 (en) 1996-10-28 1997-10-28 Novel (+)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Publications (2)

Publication Number Publication Date
NO992008D0 NO992008D0 (en) 1999-04-27
NO992008L true NO992008L (en) 1999-06-25

Family

ID=8102133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992008A NO992008L (en) 1996-10-28 1999-04-27 New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes

Country Status (8)

Country Link
EP (1) EP0934298A1 (en)
JP (1) JP2001502707A (en)
AU (1) AU4771997A (en)
CA (1) CA2269970A1 (en)
IL (1) IL129624A0 (en)
NO (1) NO992008L (en)
WO (1) WO1998018775A1 (en)
ZA (1) ZA979644B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1041258B (en) * 1998-12-30 2003-12-12 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CO5251465A1 (en) 2000-01-26 2003-02-28 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES TO TREAT OSTEOPOROSIS AND REDUCE CHOLESTEROL
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
WO2006032085A1 (en) 2004-09-21 2006-03-30 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
AU2008229617A1 (en) * 2007-03-16 2008-09-25 Novogen Research Pty Ltd Method for inducing autophagy
EP2635273B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
AU2016215515B2 (en) 2015-02-02 2020-04-30 Mei Pharma, Inc. Combination therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (en) * 1966-02-16 1969-12-11 Merck Ag E Process for the preparation of 3,4-cis-4-aryl-isoflavans
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders

Also Published As

Publication number Publication date
EP0934298A1 (en) 1999-08-11
JP2001502707A (en) 2001-02-27
ZA979644B (en) 1998-04-28
WO1998018775A1 (en) 1998-05-07
NO992008D0 (en) 1999-04-27
CA2269970A1 (en) 1998-05-07
IL129624A0 (en) 2000-02-29
AU4771997A (en) 1998-05-22

Similar Documents

Publication Publication Date Title
NO179582C (en) Analogous Process for Preparing Therapeutically Active Hydroxamic Acid and N-Hydroxyurea Derivatives
AU563748B2 (en) Quinolone carboxylic acids
HK129093A (en) N-tert-butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl)isoquinoline-3-carboxamide & asparaginyl derivatives thereof
ATE233250T1 (en) SACCHARINE DERIVATIVES AS PROTEOLYTIC ENZYMIN HIBITORS
ATE231496T1 (en) SACCHARINE DERIVATIVES AS PROTEOLYTIC ENZYMIN HIBITORS
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
NO971625L (en) Novel peptides with immunomodulatory effects
NO992003L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
BR9503572A (en) Compound pharmaceutical composition and method of treatment or prevention of a disease
NO992008L (en) New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992010L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992005L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992006L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992009L (en) New trans-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992007D0 (en) Novel (-) Enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO20045132L (en) Benzo (c) quinolizine derivatives, their preparation and use as 5alpha-reductase inhibitors
NO992002L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992004L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
FI932654A0 (en) Hydroxamsyraderivat, som hindrar lipoxigenas
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives
DK0714908T3 (en) New 17- (3-imino-2-alkylproenyl) -5beta, 14beta-androstan derivatives active in the cardiovascular system, methods
RU93030824A (en) Drug for the treatment of psoriasis "Dermapichtol"
RU93055683A (en) HIV PROTEASE INHIBITORS, METHOD FOR PRODUCING THEM, USE THEM, COMPOSITION
RU93055680A (en) HIV PROTEASIS INHIBITORS, METHOD FOR PRODUCING, USE THEM, COMPOSITION
RU94015603A (en) DERIVATIVES 3-HYDROXIANTRANIC ACID, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND INTERMEDIATE CONNECTIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application